

REMARKS

Amendments to the Claims

New claim 28 is added, which combines the features of claims 7 and 13. Claims 7 and 13 are amended to depend from claim 28. No new matter has been added.

Response to the Election of Species Requirement

The Office has required election of one species of chemotherapeutic agent from among paclitaxel, aromatase inhibitors, and TNF-related apoptosis inducing ligand. The Office indicates that should Applicants elect aromatase inhibitors or TNF-related apoptosis-inducing ligand, Applicants should further elect a disclosed species thereof of an aromatase inhibitor or a TNF-related apoptosis-inducing ligand. With regard to the requirement to elect a single disclosed species of TNF-related apoptosis-inducing ligand, Applicants respectfully point out that "TNF-related apoptosis-inducing ligand" is a term that describes a specific protein (which, according to the National Center for Biotechnology Information (NCBI) website at http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=gene&list_uids=8743 is also known as tumor necrosis factor (ligand) superfamily member 10 (TNFSF10), TL2, APO2L, CD253, or Apo-2L) rather than being a generic term. Although Applicants are not electing "TNF-related apoptosis-inducing ligand" in the present reply, should the Office require election of a single disclosed species of TNF-related-inducing ligand during the further examination of the application, the Office is respectfully requested to clarify from among which species of TNF-related-inducing ligand the Applicants should make an election. *See* MPEP 809.02(a).

Applicants elect the species wherein the chemotherapeutic agent is **paclitaxel**. The claims readable on the elected species are claims 1, 5, 7, 11, 26 and 28.

Applicant : Coleman, et al.
Serial No. : 10/578,290
Filed : May 5, 2006
Page : 5 of 5

Attorney's Docket No.: 18649-059US1 / 4-33540A

The examination of the pending claims and passage to allowance are respectfully requested and an early Notice of Allowance is earnestly solicited. Applicants invite the Examiner to contact the undersigned at (302) 778-8438 to clarify any issues outstanding in the application.

Please apply any charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: January 25, 2008

/Eifion Phillips/
Eifion Phillips, D.Phil.
Reg. No. 55,538

Fish & Richardson P.C.
P.O. Box 1022
Minneapolis, MN 55440-1022
Telephone: (302) 652-5070
Facsimile: (877) 769-7945